In-vitro regulation of primordial follicle activation: challenges for fertility preservation strategies  Michael J. Bertoldo, Kirsty A. Walters, William.

Slides:



Advertisements
Similar presentations
by Rogelio Zamilpa, and Merry L. Lindsey
Advertisements

Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.
Cancer and fertility: strategies to preserve fertility
Kay Neumann, Georg Griesinger  Reproductive BioMedicine Online 
Inositol as putative integrative treatment for PCOS
IRS-1: Auditing the effectiveness of mTOR inhibitors
Volume 142, Issue 6, Pages (May 2012)
Figure 1 mTOR pathway activation
The Akt-mTOR tango and its relevance to cancer
Figure 3 Defects in the T cell receptor signalling pathway
Kinase inhibitors: Vice becomes virtue
Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3- Kinase/AKT/Mammalian Target of Rapamycin Pathway  Gozde Akgumus, Fengqi.
Nicole Noyes, Jaime M. Knopman, Katherine Melzer, M
Claus Yding Andersen, Stine Gry Kristensen 
Sohlh2 inhibits the apoptosis of mouse primordial follicle oocytes via C- kit/PI3K/Akt/Foxo3a signalling pathway  Xiaoli Zhang, Haiyu Zhang, Qing Gao,
Figure 3 Physiological regulation of autophagy in the heart
In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation 
Rapamycin in transplantation: A review of the evidence
Rapamycin Resistance: mTORC1 Substrates Hold Some of the Answers
Alexander L. Fogel, BS, Sharleen Hill, MD, Joyce M.C. Teng, MD, PhD 
MTOR/P70S6K promotes spermatogonia proliferation and spermatogenesis in Sprague Dawley rats  Hao Xu, Lianju Shen, Xuemei Chen, Yubin Ding, Junlin He,
Figure 1 mTOR complex biology
PTEN Tumor Suppressor and Cancer
The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer  Vassiliki Papadimitrakopoulou,
Maria M. Mihaylova, David M. Sabatini, Ömer H. Yilmaz  Cell Stem Cell 
Identification of TOR Signaling Complexes
PTEN Enters the Nuclear Age
Sherman Silber  Reproductive BioMedicine Online 
Figure 1 The insulin signalling pathway
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Rapamycin: One Drug, Many Effects
Shi Ying Jin, Ph. D. , Lei Lei, Ph. D. , Ariella Shikanov, Ph. D
Eukaryotic Transcription Activation: Right on Target
FGFR Signaling as a Target for Lung Cancer Therapy
A rapidly evolving revolution in stem cell biology and medicine
Sarah McCredie, William Ledger, Christos A. Venetis 
Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405.
Autophagy in kidney disease and aging: lessons from rodent models
IRS-1: Auditing the effectiveness of mTOR inhibitors
S. Hendriks, E. A. F. Dancet, A. Meissner, F. van der Veen, M. H
The next (re)generation of ovarian biology and fertility in women: is current science tomorrow's practice?  Dori C. Woods, Ph.D., Jonathan L. Tilly, Ph.D. 
An Emerging Role of mTOR in Lipid Biosynthesis
mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
Evelyn E. Telfer, Ph.D., F.S.B., Mary B. Zelinski, Ph.D. 
Volume 18, Issue 1, Pages (July 2013)
Ronit Machtinger, Raoul Orvieto  Reproductive BioMedicine Online 
AKT/PKB Signaling: Navigating the Network
V Isachenko, E Isachenko, R Kreienberg, M Woriedh, JM Weiss 
Figure 1 The mTOR signalling pathway
Youry Kim, Jenny L. Anderson, Sharon R. Lewin  Cell Host & Microbe 
Pierre Theurey, Jennifer Rieusset  Trends in Endocrinology & Metabolism 
AKT/PKB Signaling: Navigating Downstream
TOR, the Gateway to Cellular Metabolism, Cell Growth, and Disease
Follicle recruitment determines IVF productivity rate via the number of embryos frozen and subsequent transfers  James D. Stanger, John L. Yovich  Reproductive.
Signalling links in the liver: Knitting SOCS with fat and inflammation
Rapamycin: One Drug, Many Effects
mTOR and Akt Signaling in Cancer: SGK Cycles In
Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD 
Volume 69, Issue 11, Pages (June 2006)
Brian K. Kennedy, Dudley W. Lamming  Cell Metabolism 
Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn  Kidney International 
Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing  Richard A.F. Clark,
Update on the Medical Treatment of Metastatic Renal Cell Carcinoma
Nutrient Sensing, Metabolism, and Cell Growth Control
Reproductive BioMedicine Online
Successful targeting of ErbB2 receptors—is PTEN the key?
Turning Reciprocal Feedback Regulation into Combination Therapy
The Ribosome and TORC2: Collaborators for Cell Growth
Presentation transcript:

In-vitro regulation of primordial follicle activation: challenges for fertility preservation strategies  Michael J. Bertoldo, Kirsty A. Walters, William L. Ledger, Robert B. Gilchrist, Pascal Mermillod, Yann Locatelli  Reproductive BioMedicine Online  Volume 36, Issue 5, Pages 491-499 (May 2018) DOI: 10.1016/j.rbmo.2018.01.014 Copyright © 2018 Reproductive Healthcare Ltd. Terms and Conditions

Figure 1 Fertility preservation strategies for females before cancer treatment. Treatments are tailored to patients depending on the patient's age, the possible delay in treatment and sensitivity of malignancy to hormone treatment. Experimental procedures are enclosed in green boxes. IVM = in vitro maturation. Reproductive BioMedicine Online 2018 36, 491-499DOI: (10.1016/j.rbmo.2018.01.014) Copyright © 2018 Reproductive Healthcare Ltd. Terms and Conditions

Figure 2 Culture of cortical tissue permits the activation of primordial follicles. Once follicle growth is initiated, follicles have the potential to develop into multilaminar structures up to the secondary follicle size. However, at this point of development, the cortical environment that nurtured the first stages of follicle development becomes inhibitory for growth to pass the secondary follicle stage. The pre-antral follicles can be mechanically isolated from the cortex, encapsulated in an alginate hydrogel and placed into individual culture for further differentiation to the antral stage. Following formation of the antrum, follicles can then be removed from the hydrogel and cultured in low attachment plates. Oocytes within can be mechanically extracted from the follicle and placed into IVM and subsequently undergo IVF. Adapted from Telfer and McLaughlin (2011) and Xiao et al. (2015). Reproductive BioMedicine Online 2018 36, 491-499DOI: (10.1016/j.rbmo.2018.01.014) Copyright © 2018 Reproductive Healthcare Ltd. Terms and Conditions

Figure 3 Molecular pathways regulating primordial follicle activation. The PI3K/Akt/mTOR pathway has many substrates which include molecules regulating cell cycle and apoptosis. Akt can phosphorylate Foxo3a and cause cytoplasmic localization of this transcription factor. When unphosphorylated, Foxo3a and p27 relocate to the nucleus and inhibit primordial follicle activation. Inhibition of Foxo3a translocation may also be regulated by the JNK/c-Jun pathway. Phosphorylation and inactivation of TSC by Akt leads to the activation of mTORC1. mTORC1 integrates cellular energy levels, growth factors and other signals that regulate protein translation and primordial follicle activation. 4E-BP1 = 4E binding protein; Akt = protein kinase B; EIF4B = eukaryotic translation initiation factor 4B; mTOR = mammalian target of rapamycin complex; p27 = p27kip1; PDK1 = 3′-phosphoinositide-dependent kinase-1; PI3K = phosphatidylinositol-3-kinase; PIP2 = phosphatidylinositol-4,5-biphosphate; PIP3 = phosphatidylinositol-3,4,5-triphosphate; PTEN = phosphatase and tensin homologue deleted on chromosome 10; rpS6 = ribosomal protein S6; S6K = S6 kinase; TSC = tuberin/tuberous sclerosis complex. Adapted from Adhikari and Liu (2009). Reproductive BioMedicine Online 2018 36, 491-499DOI: (10.1016/j.rbmo.2018.01.014) Copyright © 2018 Reproductive Healthcare Ltd. Terms and Conditions